- Home
- NERV vs BHAT Comparison
NERV vs BHAT Comparison
Compare NERV & BHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- BHAT
- Stock Information
- Founded
- NERV 2007
- BHAT 2010
- Country
- NERV United States
- BHAT China
- Employees
- NERV N/A
- BHAT N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- BHAT Recreational Games/Products/Toys
- Sector
- NERV Health Care
- BHAT Consumer Discretionary
- Exchange
- NERV Nasdaq
- BHAT Nasdaq
- Market Cap
- NERV 12.0M
- BHAT 12.7M
- IPO Year
- NERV 2014
- BHAT 2019
- Fundamental
- Price
- NERV $2.35
- BHAT $1.74
- Analyst Decision
- NERV Hold
- BHAT
- Analyst Count
- NERV 1
- BHAT 0
- Target Price
- NERV $5.00
- BHAT N/A
- AVG Volume (30 Days)
- NERV 41.4K
- BHAT 133.7K
- Earning Date
- NERV 11-04-2025
- BHAT 04-30-2025
- Dividend Yield
- NERV N/A
- BHAT N/A
- EPS Growth
- NERV N/A
- BHAT N/A
- EPS
- NERV 1.48
- BHAT N/A
- Revenue
- NERV N/A
- BHAT $18,724,190.00
- Revenue This Year
- NERV N/A
- BHAT N/A
- Revenue Next Year
- NERV N/A
- BHAT N/A
- P/E Ratio
- NERV $1.58
- BHAT N/A
- Revenue Growth
- NERV N/A
- BHAT N/A
- 52 Week Low
- NERV $1.15
- BHAT $1.51
- 52 Week High
- NERV $3.00
- BHAT $45.00
- Technical
- Relative Strength Index (RSI)
- NERV 59.22
- BHAT 52.54
- Support Level
- NERV $2.26
- BHAT $1.60
- Resistance Level
- NERV $2.47
- BHAT $1.92
- Average True Range (ATR)
- NERV 0.15
- BHAT 0.13
- MACD
- NERV -0.01
- BHAT 0.01
- Stochastic Oscillator
- NERV 36.71
- BHAT 54.88
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.